An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics has made significant progress in Q1 2025 towards becoming a commercial-stage drug developer, extending its cash runway to over $200 million through a $146 million Entitlement Offer. This funding supports the advancement of its drug candidates, including human trials for polycystic kidney disease and ongoing studies in Retinitis Pigmentosa, positioning the company for improved market conditions and stakeholder confidence.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing precision medicines for genetic diseases with no current treatment options. The company leverages its proprietary drug delivery platform to enhance RNA therapies, targeting monogenic diseases for higher clinical success rates.
YTD Price Performance: -24.43%
Average Trading Volume: 545,764
Technical Sentiment Signal: Buy
Current Market Cap: A$545.4M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.